Our lab is hiring a talented senior computational biologist to unravel the impact of the microbiome and FMT in immumo-oncology Arielle Elkrief, MD FRCPC Centre de recherche du CHUM Université de Montréal

An estimated 11,300 Canadians are expected to be diagnosed with melanoma this year.

That’s why we are proud to be uniting with a team of 12 researchers and collaborators to lead one of the world’s largest randomized clinical trials using fecal microbiota transplantation to

New job opportunity! Our labs with Arielle Elkrief, MD FRCPC at the CHUM Microbiome Centre are looking for a senior Computational Biologist with expertise in microbiome. Link to job posting:
Come join an amazing team bringing microbiome trials to patients

chumontreal.qc.ca/en/emplois/pos…

Celebrating 6 years of the Routy lab with the best team

Gut microbiome and treatment efficacy. Not solely for immunotherapy. Thanks to ⁦Bertrand Routy MD,PhD⁩ lab sciencedirect.com/science/articl…

Characterization and description of Gabonibacter chumensis sp. nov., isolated from feces of a patient with non-small cell lung cancer treated with immunotherapy.
doi.org/10.1007/s00203…
#Gabonibacter
Centre de recherche du CHUM
Bertrand Routy MD,PhD
Bastien Castagner
McGill University
UNCG
#ArchivesOfMicrobiology

Dear Terry, we will never stop running for you and people living with cancer. Thank you for your support ⁦TerryFoxFoundation⁩ ⁦Terry Fox Research Institute⁩ ⁦Centre de recherche du CHUM⁩

We are soon to begin a trial of camu camu with IO in kidney cancer, inspired by Bertrand Routy’s excellent paper in Cancer Discovery, at City of Hope - Sumanta K. Pal, MD, FASCO
Bertrand Routy MD,PhD Cancer Discovery City of Hope Regina Barragan-Carrillo

#Cancer #CityOfHope #OncoDaily #Oncology

oncodaily.com/7688.html

Following the discovery of prebiotic castalagin ⁦Meriem Messaoudene⁩ in ⁦AACR⁩, first off-label evidence of efficacy in cancer refractory to IO ⁦McGill University⁩. Encouraging for ongoing trial NCT05303493 Centre de recherche du CHUM⁩ by ⁦Arielle Elkrief, MD FRCPC⁩ mdpi.com/1718-7729/30/9…

As a belated gift for the #microbiomeday we continue to add a new bacteria isolated from a Montrealer. Centre de recherche du CHUM Culturomics is key to expand our knowledge!

academic.oup.com/femsle/advance…

Wonderful collaboration with Nicola Segata Jennifer Wargo MD Gustave Roussy to integrate metagenomics data and define oncomicrobiome signatures of IO response nature.com/articles/s4157… NatureRevClinOncol Centre de recherche du CHUM. Let’s continue to profile cancer microbiome!

ATB-related dysbiosis is a real phenomenon associated with IO resistance. After meta-analyses and microbiome profiling papers, first mechanistic study unraveling that ATB alter gut checkpoint MadCam and IO response👍 lisaderosa Gustave Roussy Centre de recherche du CHUM science.org/doi/10.1126/sc…

What’s next after 1L chemo-immuno in #NSCLC ? Check this study led by Edouard Auclin just out in Lung Cancer Journal. Better disease control with platinum rechallenge and taxane+antiangiogenic.
Laura Mezquita Benjamin Besse Bertrand Routy MD,PhD OncoAlert #lcsm
doi.org/10.1016/j.lung…

' #GutMicrobiota plays an important role in surgical #colonic healing in #patients with #ColorectalCancer ', a Gut Journal study on mice.

Roy Hajjar Emmanuel Gonzalez Bertrand Routy MD,PhD Nicholas Brereton Centre de recherche du CHUM CHUM Faculté de médecine
👇
gut.bmj.com/content/early/…

#cancer | Une étude de la Dre Marion Tonneau – équipe du Dr Bertrand Routy MD,PhD – révèle que la présence d’anticorps liés à une infection à la bactérie H. pylori diminuerait la réponse à l' #immunothérapie en cas de #mélanome métastatique.
Faculté de médecine
nouvelles.umontreal.ca/article/2023/0…

👇👇👇

Dr. Routy will use funds from his @MarathonofHope Clinician-Scientist Award to perform multi-omics sequencing to see how these interventions affect the gut microbiome, and whether they have a downstream impact on immunotherapy response.

The recipients are:

1⃣. Dr. Bertrand Routy, Centre de recherche du CHUM (Montreal) for: How microbiomes influence intratumour immune contexture and response to immune-checkpoint inhibitors in patients with non-small cell lung cancer #LungCancer

More ▶️ bit.ly/3USWJCN Bertrand Routy MD,PhD

Glad to be in Boston today - Pass by the poster area and say hi at poster 1300 for a quick chat about CT scan normalization to improve radiomics generalizability #SITC22 Bertrand Routy MD,PhD Imagia Canexia Health Centre de recherche du CHUM Université de Lille Society for Immunotherapy of Cancer